Articles tagged with Chemotherapy
Researchers at Fox Chase Cancer Center discovered a novel DNA-repair gene mutation that causes resistance to cancer drugs, particularly in colorectal cancer. The defective MED1 enzyme interferes with chemotherapy's effectiveness, making cancers resistant to widely used treatments.
Researchers found decreased tumor blood flow correlated significantly with survival in patients treated with neoadjuvant chemotherapy. The study suggests tumor biology should be an important factor in considering patient response to treatment.
Researchers used transarterial chemoembolization (TACE) to treat patients with liver tumors, shrinking them by up to 35% in size. Patients who responded successfully were then treated with laser-induced thermotherapy (LITT), allowing for a more aggressive approach to tumor treatment while preserving patient quality of life.
Women with BRCA1 mutations have a poorer prognosis for breast cancer compared to those without the mutation. However, chemotherapy may improve survival rates for these patients. The study suggests that physicians should consider BRCA1 mutation status when making treatment decisions.
Researchers at Johns Hopkins Kimmel Cancer Center have discovered a gene silencer that blocks cancer cells' ability to repair themselves after chemotherapy and radiation. By reducing the production of targeted repair proteins, the silencer enables cancer cells to become susceptible to therapy.
A new study found that adding aprepitant to standard treatment for nausea and vomiting can effectively prevent these symptoms following chemotherapy. The medication reduced nausea and vomiting both on the day of chemotherapy administration and in the days that followed.
A study found that using aggressive chemotherapy with high doses of methotrexate, asparaginase, and doxorubicin improves survival rates for children with T-cell acute lymphoblastic leukemia by 15 percentage points. The new approach also showed minimal long-term effects beyond those seen in lower-dose treatment regimens.
A new study found that adjuvant chemotherapy did not improve survival rates for patients with surgically removed non-small-cell lung cancer. Additionally, a study on selenium supplementation revealed that it may increase the risk of squamous cell carcinoma and total nonmelanoma skin cancer in individuals at high risk.
A large-scale clinical study by Nordic collaboration has provided new insights into the effects of chemotherapy in colorectal cancer. The analysis demonstrated that among 2,223 patients, those given chemotherapy as part of routine care had a five-year survival rate of 56%, compared to 49% for those treated by surgery alone.
A multi-center study found improved overall survival and time to disease progression for women with metastatic breast cancer treated with Taxotere, compared to paclitaxel. The results suggest that Taxotere may be a more effective treatment option for this patient population.
A Phase III trial found that docetaxel significantly improved survival rates and overall response rates compared to paclitaxel in women with advanced, incurable breast cancer. The median survival time was 15.4 months for docetaxel patients versus 12.7 months for paclitaxel patients.
A meta-analysis of 14 trials showed no survival benefit with chemotherapy, but adjuvant radiotherapy resulted in a 7% higher mortality rate. Professor Thatcher suggests further research is needed to confirm the result.
A Phase III study shows that Avastin, an anti-angiogenic agent, extends patient survival time to 20.3 months when added to first-line chemotherapy. The treatment also improves response rates and duration of response across all relevant patient subgroups.
Two new studies found that elderly lung cancer patients benefit equally from aggressive chemotherapy and radiation treatment, contradicting common assumptions. Fit elderly patients should be fully briefed on treatment options, including potential risks and benefits. The studies suggest presenting the full range of treatment options to ...
A new study reveals that patients who received neoadjuvant chemotherapy lived an average of 31 months longer than those treated with surgery alone. The combination therapy showed a 66% greater chance of surviving bladder cancer.
A chemist's research creates tools to make complex drugs more efficiently, with potential breakthroughs in anti-cancer treatments. His work has led to licenses for pharmaceutical companies to study promising drug candidates.
A renowned chemist has synthesized epothilone, a compound derived from bacteria, promising to replace taxol in treating cancer. His successful 25-step synthesis has garnered interest from pharmaceutical companies, paving the way for potential clinical trials and widespread use.
Dr. Rawal has developed a rapid and straightforward reaction that can assemble pieces of complex molecules with high accuracy. This innovation is expected to improve the performance of anticancer drugs like vincristine, which has been used successfully in treating childhood leukemia.
A new combination cancer-killing drug regimen has shown promising results in extending patient survival, with 16% tumor shrinkage and 35% stable disease progression after six months. The orally administered treatment has been well-tolerated and offers a more convenient option for patients compared to traditional IV chemotherapy.
A study found that delaying chemotherapy until disease progression was equivalent to immediate treatment in overall survival and specific survival rates. Patients aged over 70 had a higher chance of not requiring chemotherapy after 10 years.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
A new gene expression profile test could identify which breast cancer patients are likely to respond to chemotherapy, helping reduce unproductive treatment and toxicity. The test uses biopsy samples from primary tumors before treatment and measures the tumor's response to docetaxel.
Combining herbal supplements with regular medication without consulting a doctor can lead to adverse interactions. Patients should discuss their herbal supplement use with their primary physician to ensure safe treatment and prevent unexpected complications.
A Canadian-led study found that about 83% of colon cancer patients benefit from traditional chemotherapy, while nearly 17% do not. Further research is needed to provide alternative treatments for those who don't respond to standard therapy.
Researchers have developed novel compounds that significantly improve anti-cancer therapy outcomes. The AvastinTM clinical trial shows that bevacizumab, an anti-angiogenesis agent, can slow or stop tumor growth and increase patient survival when combined with chemotherapy.
A Phase III trial found that pemetrexed and cisplatin significantly improved one-year survival rates for mesothelioma patients to 56.5%, compared to 41.9% for those receiving only cisplatin.
CYC202 demonstrates significant cancer cell death, with 54% of patients testing positive for apoptosis following single agent treatment. Seven patients experienced long-lasting tumour stabilisation in Phase I trials, showcasing potential for selective treatment based on genetic profiles.
A national study found that 43% of patients reported nausea on the day of treatment, and 73% experienced nausea one or more days later. Delayed nausea is a significant problem, affecting twice as many patients who felt ill in the following days compared to those who felt queasy initially.
A randomized clinical trial of over 500 women with primary breast cancer found no significant improvement in disease-free survival or overall survival with high-dose chemotherapy and stem cell transplantation. However, time to recurrence was longer for patients who received the treatment.
A recent study found that high-dose chemotherapy followed by autologous stem cell transplant did not significantly increase survival rates for women with early stage breast cancer. The study, which included 511 patients, showed a higher number of relapses in the treatment group but also nine deaths due to transplantation complications....
Women treated with radiation therapy and chemotherapy had a 61% lower risk of developing breast cancer compared to those who received only radiation. The authors suggest that ovarian hormones play a role in promoting tumor growth after radiation, which may explain the increased breast cancer risk in young women exposed to radiation.
A phase 2 clinical trial found that bortezomib responded positively in 193 relapsed patients, including seven with undetectable myeloma protein and 12 with detectable protein only with immunofixation. The results confirmed significant clinical benefits from therapy.
Researchers found that patients with a negative pretransplantation scan had a favorable outcome, with 25 still in complete remission after a median follow-up of 1,510 days. In contrast, patients with a positive scan relapsed more frequently, highlighting the potential for [F]FDG-PET to identify nonresponders.
Researchers at St. Jude Children's Hospital have successfully treated four pediatric patients with retinoblastoma using a combination of chemotherapy, radiation therapy, and stem-cell transplantation. The study shows promising results, with two out of four patients surviving for over six years without disease recurrence.
A study by Te Velde found that the Pringle manoeuvre increases tumour growth and recurrence after liver surgery, reducing patient survival chances. Medicines preventing blood vessel regeneration can be combined with chemotherapy to control tumours.
Contrast-enhanced MRI is a reliable method to measure blood flow to tumors, allowing for accurate assessment of chemotherapy response and tumor viability. The study found that patients who responded to treatment had significant decreases in angiogenesis, while non-responders showed increases.
A study by Dr. Pio and colleagues found that FLT-PET imaging outperforms FDG-PET in predicting tumor response to chemotherapy in breast cancer patients. The researchers compared the two imaging modalities in 11 newly diagnosed patients, taking scans before treatment began, after the first dose, and following the final cycle.
Pregnant women should undergo thorough breast examinations to detect breast cancer, as diagnosis is often delayed due to hormonal changes. Ultrasonography is the best method for detecting cancerous lumps during pregnancy.
Chemoembolization is the treatment of choice for widespread or diffuse tumors, enabling patients with primary liver cancer to live longer and maintain a quality of life. The procedure uses oil droplets to transport chemotherapy agents directly to the tumor, reducing toxicity and improving outcomes.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Susan Bane's research focuses on understanding how anticancer drugs like Taxol interact with tubulin at the molecular level. The study of these interactions could pave the way for the development of more effective next-generation cancer drugs, potentially with improved administration and reduced resistance.
The study found that BAC proliferation correlated with HER2 but not EGFR expression, suggesting a potential role for combination therapies. Researchers hope to launch a clinical trial of HER2- and EGFR-blocker combination therapy in the treatment of BAC.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
A new monoclonal antibody combination therapy has been found to be highly effective in treating chronic lymphocytic leukemia, with a remarkable 69% complete remission rate. The treatment, which combines two chemotherapy drugs with Rituximab, shows promising results across all age groups and stages of the disease.
A new chemotherapy regimen combining docetaxel with cisplatin and 5-Fluorouracil has been shown to significantly improve survival rates in late-stage stomach cancer patients. The study found a nearly 80% higher chance of tumor shrinkage and a reduced risk of cancer growth.
A new study found that chemotherapy and radiotherapy together reduce surgery and removal of the voice box due to cancer recurrence. The combination treatment was associated with a significantly lower rate of surgeries compared to standard therapy or radiotherapy alone.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a gene screen that can accurately predict which chemotherapy regimens will be effective for patients with newly diagnosed breast cancer. The test is 75% accurate in forecasting complete eradication of cancer, eliminating the need for trial and error.
Bevacizumab significantly extends survival time for metastatic colorectal cancer patients by shrinking tumors and inhibiting tumor growth. The study showed a median survival increase of five months compared to standard chemotherapy alone, with significant delays in cancer progression.
Researchers at Stanford have shown positive results with a new chemotherapy combination, Iressa and FOLFOX, in treating colon cancer. The treatment has been effective in shrinking tumors by up to 75% in patients who had never received chemotherapy before.
A new DNA array technology test has identified differences in gene patterns that predict which breast cancer patients will respond to chemotherapy. The study, led by Dr. Jenny Chang at Baylor College of Medicine, found that 88% of genes were correctly classified, allowing for personalized treatment strategies.
The GELA study reveals that MabThera plus CHOP improves three-year event-free survival by 18% and overall survival by 11%, with no increased toxicity. This breakthrough treatment offers a potential cure for aggressive NHL, which affects 55% of the 1.5 million people worldwide suffering from non-Hodgkin's lymphoma.
Researchers found that gefitinib can slow lung cancer tumor recurrence when used as maintenance therapy following chemotherapy. The study suggests that gefitinib may keep cancer cells dormant for a period of time.
Researchers at Memorial Sloan Kettering Cancer Center found that targeted therapy erlotinib caused dramatic tumor regressions in some patients with BAC, particularly those who never smoked. The treatment was effective in 25% of patients with advanced BAC, offering a new approach to managing this disease.
A Phase II study shows that administering ADVEXIN, a p53 drug, directly to tumors can improve the results of neoadjuvant chemotherapy in locally advanced breast cancer. The treatment resulted in dramatic tumor shrinkage and minimal residual tumor cells.
USC researchers have identified a protein fragment, PEP, that can increase the effectiveness of chemotherapy drugs against tumors. By making tumor blood vessels more permeable, PEP allows for better drug uptake and increased chemotherapy efficacy.
Researchers discover that ovarian tumor cells can 'switch back' to a normal state, making them vulnerable to chemotherapy. This finding represents a crucial step toward the discovery of new anti-cancer drugs.
Researchers treated 18 patients with lung nodules using radiofrequency ablation, achieving a 97% destruction rate. The treatment was found to be short-lasting and manageable, with most complications resolved within a week.
A Phase II study found that the DVd regimen showed a high response rate of 88%, with 12% achieving complete response. The treatment was well-tolerated, with the most common Grade 3 or 4 toxicity being palmar-plantar erythrodysesthesia. Improved patient education and prevention measures reduced toxicity incidence.